Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 7937386.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Low molecular weight heparins are providing a new prophylactic option for preventing deep vein thrombosis (DVT) in patients undergoing joint replacement surgery. Fragmentation of heparin in laboratory studies revealed differences in coagulation and bleeding factors. This unexpected finding led to clinical trials, starting in 1985 in Europe and the United States. By late 1993, more than 10,000 patients had been admitted to clinical trials of low molecular weight heparins (LMWH) for prevention of DVT. Results of these trials indicated that LMWHs were more effective than unfractionated heparins or warfarin in preventing DVT with no significant increase in bleeding noted.
Medical subject headings
- Heparin, Low-Molecular-Weight
- Hip Prosthesis
- Knee Prosthesis
- Postoperative Complications
- Thromboembolism
Anatomy
- hip
- knee